|
Kanestri V.G., Kravchenko A.V., Gankina N.Yu.
Hepatotoxicity of antiretroviral therapy in HIV-infected patients
|
№1 / 2015
|
|
Yurin O.G., Kravchenko A.V., Kanestri V.G., Pokrovskaya A.V., Shakhgildyan V.I., Volkova S.B.
Dual antiretroviral therapy with lopinavir and ritonavir
|
№6 / 2014
|
|
Kozyrina N.V., Narsia R.S., Yurin O.G.
Abacavir and lamivudine as a nucleoside base of antiretroviral therapy
|
№5 / 2014
|
|
Mikova O.E., Moiseeva G.V.
Use of a combination of the antiretroviral drugs darunavir® and etravirine® in a patient with a resistant HIV strain
|
№4 / 2014
|
|
Moskvicheva M.G., Radzikhovskaya M.V.
Experience with the HIV protease inhibitor fosamprenavir in first-line antiretroviral therapy regimens in the Chelyabinsk Region
|
№3 / 2014
|
|
Khasanova G.R.
Lipodystrophy syndrome in patients with HIV infection
|
№3 / 2014
|
|
Beketova E.V., Bykov S.A.
Experience with enfuvirtide (fuzeon) in the treatment regimens for HIV infection
|
№2 / 2014
|
|
Kanestri V.G.
Contribution of a fixed-dose abacavir/lamivudine combination to improving treatment compliance in HIV-infected patients
|
№6 / 2013
|
|
Gushchina Yu.Sh., Kubaeva M. B.
Prospects for the long-term efficaсay of fosamprenavir (telzir) used as part of antiretroviral therapy in hiv-infected patients
|
№6 / 2013
|
|
Pyadushkina E.A., Goryaynov S.V., Omelyanovsky V.V., Avxentyeva M.V., Rebrova O.Yu.
Clinicoeconomic analysis of the use of maraviroc versus other reserve drugs in patients who have experienced antiretroviral therapy for HIV infection
|
№5 / 2013
|
|
Volkova S.B., Podymova A.S.
Experience with the HIV protease inhibitor fosamprenavir in russian practice
|
№4 / 2013
|
|
Sundukov A.V., Gafurov Yu.T., Evsyukov O. A.
Clinical and laboratory features of abnormalities in the cervix uteri, external genitals, and vagina in HIV-infected patients
|
№4 / 2013
|
Русский
